Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC)

Summary

This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic cells in patients with advanced or recurrent epithelial ovarian cancer

Timeline

Start

2021-03-30

Primary completion

2022-05-10

Completion

2022-05-10

Outcome

Outcome not reported

Stopped (Enrollment): “Difficult recruitment”

Drugs

Indications